Terms: = Germ cell tumor AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
1204 results:
1. Principles in the Management of Glioblastoma.
Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
[TBL] [Abstract] [Full Text] [Related]
2. Survival Outcome Prediction in Glioblastoma: Insights from MRI Radiomics.
Styliara EI; Astrakas LG; Alexiou G; Xydis VG; Zikou A; Kafritsas G; Voulgaris S; Argyropoulou MI
Curr Oncol; 2024 Apr; 31(4):2233-2243. PubMed ID: 38668068
[No Abstract] [Full Text] [Related]
3. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract] [Full Text] [Related]
4. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
5. GPR27 expression correlates with prognosis and tumor progression in gliomas.
Cai C; Hu L; Wu K; Liu Y
PeerJ; 2024; 12():e17024. PubMed ID: 38638156
[TBL] [Abstract] [Full Text] [Related]
6. DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.
Caffo M; Casili G; Caruso G; Barresi V; Campolo M; Paterniti I; Minutoli L; Ius T; Esposito E
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612910
[TBL] [Abstract] [Full Text] [Related]
7. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract] [Full Text] [Related]
8. Oligodendroglioma, idh-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.
Sasaki H; Kitamura Y; Toda M; Hirose Y; Yoshida K
Brain Tumor Pathol; 2024 Apr; 41(2):43-49. PubMed ID: 38564040
[TBL] [Abstract] [Full Text] [Related]
9. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
10. REVOLUMAB: A phase II trial of nivolumab in recurrent idh mutant high-grade gliomas.
Picca A; Touat M; Belin L; Gourmelon C; Harlay V; Cuzzubbo S; Cohen-Jonathan Moyal E; Bronnimann C; Di Stefano AL; Laurent I; Lerond J; Carpentier C; Bielle F; Ducray F; Dehais C;
Eur J Cancer; 2024 May; 202():114034. PubMed ID: 38537315
[TBL] [Abstract] [Full Text] [Related]
11. Spatially Resolved Microglia/Macrophages in Recurrent Glioblastomas Overexpress Fatty Acid Metabolism and Phagocytic Genes.
Mistry AM; Daneshmand J; Seo SJ; Lehman NL; Miller DM; Goodin DA; Frieboes HB; Chen J; Masters A; Williams BJ; Yaddanapudi K
Curr Oncol; 2024 Feb; 31(3):1183-1194. PubMed ID: 38534921
[TBL] [Abstract] [Full Text] [Related]
12. Multi-scale feature fusion for prediction of idh1 mutations in glioma histopathological images.
Liu X; Hu W; Diao S; Abera DE; Racoceanu D; Qin W
Comput Methods Programs Biomed; 2024 May; 248():108116. PubMed ID: 38518408
[TBL] [Abstract] [Full Text] [Related]
13. Intratumoral histological and molecular heterogeneity in an adult diffuse glioma.
Yogaretnam T; Heffernan J; Leung R; Heeney C; Walsh A; Looby S; Caird J; Brett FM
Clin Neuropathol; 2024; 43(2):60-64. PubMed ID: 38495012
[TBL] [Abstract] [Full Text] [Related]
14. Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial.
Hudson EM; Noutch S; Webster J; Brown SR; Boele FW; Al-Salihi O; Baines H; Bulbeck H; Currie S; Fernandez S; Hughes J; Lilley J; Smith A; Parbutt C; Slevin F; Short S; Sebag-Montefiore D; Murray L
BMJ Open; 2024 Mar; 14(3):e078926. PubMed ID: 38458809
[TBL] [Abstract] [Full Text] [Related]
15. DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma.
Ma S; Pan X; Gan J; Guo X; He J; Hu H; Wang Y; Ning S; Zhi H
Epigenetics; 2024 Dec; 19(1):2318506. PubMed ID: 38439715
[TBL] [Abstract] [Full Text] [Related]
16. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
17. Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study.
Qiao W; Wang Y; Luo C; Wu J; Qin G; Zhang J; Yao Y
BMC Cancer; 2024 Feb; 24(1):274. PubMed ID: 38418976
[TBL] [Abstract] [Full Text] [Related]
18. Mechanical characteristics of glioblastoma and peritumoral tumor-free human brain tissue.
Kren J; Skambath I; Kuppler P; Buschschlüter S; Detrez N; Burhan S; Huber R; Brinkmann R; Bonsanto MM
Acta Neurochir (Wien); 2024 Feb; 166(1):102. PubMed ID: 38396016
[TBL] [Abstract] [Full Text] [Related]
19. Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
Bobholz SA; Hoefs A; Hamburger J; Lowman AK; Winiarz A; Duenweg SR; Kyereme F; Connelly J; Coss D; Krucoff M; Banerjee A; LaViolette PS
J Neurooncol; 2024 Apr; 167(2):233-241. PubMed ID: 38372901
[TBL] [Abstract] [Full Text] [Related]
20. Identification and validation of a novel 9-gene signature of non-specific classification to predict prognosis in glioma patients.
Li G; Niu X; Li X; Lin B; Yang F; Wang Z
Cell Mol Biol (Noisy-le-grand); 2024 Jan; 70(1):134-142. PubMed ID: 38372105
[TBL] [Abstract] [Full Text] [Related]
[Next]
